Kezar Life Sciences (KZR) to Release Earnings on Tuesday

Kezar Life Sciences (NASDAQ:KZR) is expected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($1.39) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 9:30 AM ET.

Kezar Life Sciences Stock Performance

Shares of Kezar Life Sciences stock opened at $6.43 on Tuesday. The stock has a market cap of $47.07 million, a price-to-earnings ratio of -0.76 and a beta of 0.53. The firm’s 50-day moving average is $6.50 and its 200 day moving average is $5.85. Kezar Life Sciences has a 1 year low of $3.53 and a 1 year high of $7.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.07 and a quick ratio of 7.06.

Hedge Funds Weigh In On Kezar Life Sciences

A number of hedge funds have recently bought and sold shares of the business. Woodline Partners LP purchased a new stake in Kezar Life Sciences during the first quarter valued at approximately $125,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Kezar Life Sciences in the 3rd quarter worth $51,000. Geode Capital Management LLC increased its stake in shares of Kezar Life Sciences by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 68,167 shares of the company’s stock worth $429,000 after purchasing an additional 2,665 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Kezar Life Sciences by 14.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock worth $167,000 after purchasing an additional 3,312 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Kezar Life Sciences by 13.3% in the 4th quarter. Renaissance Technologies LLC now owns 131,285 shares of the company’s stock worth $826,000 after purchasing an additional 15,400 shares during the period. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a report on Monday, December 22nd. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $6.00.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.